Skip to content
DataLookout
Menu

IBOPNCT07923877

Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal Cancer

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Laryngectomy free survival (LFS)
Timeframe: Up to 2 years

Secondary (8)

Overall survival (OS)
Progression-free survival (PFS)
LFS among induction responders
Pathologic response rate of laryngectomy patients only
Partial pathologic response rate of laryngectomy patients only
Show 3 moreShow less
Radiographic response for all patients after induction
Radiographic objective response rate
Radiographic disease control rate

Arms and interventions

Arm I (induction therapy, laryngectomy)Experimental

Patients receive induction therapy with carboplatin, paclitaxel IV and pembrolizumab IV over 30 minutes every 3 weeks for up to 2-3 cycles. After induction, patients undergo standard of care laryngectomy followed by adjuvant RT and chemotherapy if indicated. Additionally, patients undergo blood and drain fluid sample collection, CT, and PET/CT throughout the study.

Arm II (induction therapy, RT, cisplatin)Experimental

Patients receive induction therapy with carboplatin, paclitaxel IV and pembrolizumab IV over 30 minutes every 3 weeks for up to 2-3 cycles. After induction, patients undergo IMRT or intensity modulated proton therapy QD on Monday-Friday weekly for up to 18 treatment fractions. Patient may also receive cisplatin IV over 30 minutes to 4 hours weekly during radiation therapy. Additionally, patients undergo blood sample collection, CT, and PET/CT throughout the study.

Procedures: Biospecimen Collection, Computed Tomography, Intensity-Modulated Proton Therapy, Laryngectomy, Positron Emission Tomography

Drugs: Carboplatin, Chemotherapy, Cisplatin, Paclitaxel

Other: Electronic Health Record Review, Questionnaire Administration

Radiation: Intensity-Modulated Radiation Therapy, Radiation Therapy

Biologicals: Pembrolizumab

Sites

1 site in 1 country

  • Mayo Clinic in RochesterRochester, Minnesota, United States